(Q45371067)

English

A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer

scientific article published on 19 November 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

phase I clinical trial

0 references

oncolytic virus

1 reference

based on heuristic

inferred from title

author name string

A Nakao

1

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

H Kasuya

2

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

T T Sahin

3

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

N Nomura

4

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

A Kanzaki

5

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

M Misawa

6

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

T Shirota

7

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

S Yamada

8

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

T Fujii

9

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

H Sugimoto

10

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

T Shikano

11

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

S Nomoto

12

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

S Takeda

13

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Y Kodera

14

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Y Nishiyama

15

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

publication date

19 November 2010

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Cancer Gene Therapy

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

18

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

167-175

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

https://scigraph.springernature.com/pub.10.1038/cgt.2010.65

0 references

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.65

21 January 2018

Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.65

21 January 2018

The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.65

21 January 2018

HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.65

21 January 2018

Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.65

21 January 2018

A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.65

21 January 2018

Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.65

21 January 2018

Changes in pancreatic cancer mortality, period patterns, and birth cohort patterns in Japan: analysis of mortality data in the period 1968-2002.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.65

21 January 2018

Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.65

21 January 2018

Intratumoral injection of herpes simplex virus HF10 in recurrent breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.65

21 January 2018

Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.65

21 January 2018

Clinical experiment of mutant herpes simplex virus HF10 therapy for cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.65

21 January 2018

Considerations for intravascular administration of oncolytic herpes virus for the treatment of multiple liver metastases

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.65

21 January 2018

Critical issues in response evaluation on computed tomography: lessons from the gastrointestinal stromal tumor model

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.65

21 January 2018

Reovirus therapy of tumors with activated Ras pathway

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.65

21 January 2018

Selectivity of an oncolytic herpes simplex virus for cells expressing the DF3/MUC1 antigen

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.65

21 January 2018

Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.65

21 January 2018

Requirement of an integrated immune response for successful neuroattenuated HSV-1 therapy in an intracranial metastatic melanoma model

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.65

21 January 2018

Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.65

21 January 2018

Effects of tumor selective replication-competent herpes viruses in combination with gemcitabine on pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.65

21 January 2018

Intelligent design: combination therapy with oncolytic viruses

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.65

21 January 2018

Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.65

21 January 2018

HSV-1 therapy of primary tumors reduces the number of metastases in an immune-competent model of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2010.65

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/CGT.2010.65

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45371067&oldid=2133465991"